Shanghai JMT-Bio Inc.

Quick facts

Phase 3 pipeline

• HB1801 · Oncology
  HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.
• JMT101 injection · Immunology
  JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system.
• JMT103 · Diabetes
  JMT103 is a small molecule that targets the SGLT2 receptor.
• KN026 · Oncology
  KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells.
• Osimertinib tablet · Oncology
  Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, blocking downstream signaling in cancer cells.
• SG001 · Diabetes
  SG001 is a small molecule drug that targets the SGLT2 receptor.

Phase 2 pipeline

• Cyclosporin Capsules · Immunology
  Cyclosporin Capsules inhibit calcineurin, preventing T-cell activation and proliferation.
• JMT601

Phase 1 pipeline

• Anti-RANKL Monoclonal Antibody · Osteoporosis
  Inhibits RANKL
• JMT108
• JMT202
• JMT206
• Placrbo · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Shanghai JMT-Bio Inc. portfolio CI brief
• Shanghai JMT-Bio Inc. pipeline updates RSS